No Detail Found!

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature

Author(s)
Asfandyar Khattak Department of Medicine, Khyber Medical University,Peshawar,Pakistan
Hira Zaffar Khattak Department of Dentistry, Peshawar Dental College,Peshawar,Pakistan
Abstract
Type 2 diabetes mellitus (T2DM) is highly prevalent in the modern world due to a rise in obesity. Diabetes can give rise to many secondary ailments among which heart failure is the most common. Heart failure brings about confirmatory changes in the myocardium which shifts the metabolism from glucose to fatty acid which further impairs cardiac function. Among the antidiabetic agents, SGLT2 inhibitors such as empagliflozin and dapagliflozin have decreased heart failure exacerbations even in the absence of diabetes. We employed search engines such as Google Scholar, MEDLINE, and Euro PMC for our article search. The keywords such as heart failure, SGLT2 inhibitors, and diabetes were used. Duplicate studies were excluded during our analysis. According to the literature, several theories have been put forward on the mechanisms through which SGLT2 inhibitors can work in heart failure. Mainly they work by lowering blood pressure, improvement of cardiac energy metabolism, anti-inflammatory efect, protecting from cardiac remodeling, diuresis, and natriuretic efects.
Publication Details
Page(s) 60-65
Published Journal: Liaquat National Journal of Primary Care, Volume: 6, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Diabetes mellitus, Diabetes mellitus, Metabolism, Heart failure, Sodium-Glucose Transporter 2 Inhibitors, diuresis
References
Ogurtsova K,da Rocha Fernandes JD,Huang Y,Linnenkamp U,Guariguata L,Cho NH .2017 .IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract, 03 : 40-50.
Jr Custodio,Duraes AR,Abreu M,Albuquerque Rocha N,Roever L .2018 .SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev, 23(3) : 409-18.
Lehrke M,Marx N. .2017 .Diabetes mellitus and heart failure. Am J Med, 04(6S) : S40-S50.
Martens P,Mathieu C,Verbrugge FH .2017 .Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med, 19(3) : 23.
Zinman B,Wanner C,Lachin JM,Fitchett D,Bluhmki E,Hantel S .2015 .Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 373(22) : 2117-28.
Scirica BM,Bhatt DL,Braunwald E,Steg PG,Davidson J,Hirshberg B .2013 .Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 369(14) : 1317-26.
Vallon V,Platt KA,Cunard R,Schroth J,Whaley J,Thomson SC .2011 .SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol, 22(1) : 104-12.
DeFronzo RA,Norton L,Abdul-Ghani M .2016 .Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol, 13(1) : 11-26.
Rahmoune H,Thompson PW,Ward JM,Smith CD,Hong G,Brown J .2005 .Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. 54.12.3427, 54(12) : 3427-34.
Rossetti L,Smith D,Shulman GI,Papachristou D,DeFronzo RA .1987 .Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest, 79(5) : 1510-5.
Abdul-Ghani MA,DeFronzo RA,Norton L .2013 .Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes, 62(10) : 0604-8.
Hadjadj S,Rosenstock J,Meinicke T,Woerle HJ,Broedl UC .2016 .Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care, 39(10) : 0522-28.
Pham SV,Chilton R.,EMPA-REG OUTCOME .2017 .The cardiologist's point of view. Am J Med, 04(6S) : S57-S62.
de Boer IH,Bangalore S,Benetos A,Davis AM,Michos ED,Muntner P .2017 .Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care, 40(9) : 0026-84.
Mazidi M,Rezaie P,Gao HK,Kengne AP .2017 .6(6): e004007. J Am Heart Assoc, : .
Weber MA,Mansfield TA,Cain VA,Iqbal N,Parikh S,Ptaszynska A .2016 .Blood pressure and glycaemic efects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebocontrolled, phase 3 study. Lancet Diabetes Endocrinol, 8587(15) : 00417-9.
Kario K,Böhm M,Mahfoud F,Townsend RR,Weber MA,Patel M .2018 .Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 138(15) : 1602-4.
Chilton R,Tikkanen I,Cannon CP,Crowe S,Woerle HJ,Broedl UC .2015 .Efects of empagliflozin on blood pressure and markers of arterial stifness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab, 17(12) : 1180-93.
Lopaschuk GD,Ussher JR,Folmes CD,Jaswal JS,Stanley WC .2010 .Myocardial fatty acid metabolism in health and disease. Physiol Rev, 90(1) : 207-58.
AbouEzzeddine OF,Kemp BJ,Borlaug BA,Mullan BP,Behfar A,Pislaru SV .2019 .: e006240. Circ Heart Fail, 12(10) : .
Ferrannini E,Muscelli E,Frascerra S,Baldi S,Mari A,Heise T .2014 .Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest, 124(2) : 499-508.
Ferrannini E,Baldi S,Frascerra S,Astiarraga B,Heise T,Bizzotto R .2016 .Shift to fatty substrate utilization in response to sodiumglucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes, 65(5) : 1356-5.
Verma S,Rawat S,Ho KL,Wagg CS,Zhang L,Teoh H .2018 .Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci, 07(5) : 575-87.
Santos-Gallego CG,Requena-Ibanez JA,Ishikawa K,Watanabe S,Picatoste B .2019 .Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol, 01(15) : 1931-44.
Dick SA,Epelman S. .2016 .Chronic heart failure and inflammation: what do we really know?. Circ Res, 119(1) : 159-76.
Mehta JL,Pothineni NV .2016 .Inflammation in heart failure: the holy grail. Hypertension, 68(1) : 27-9.
Briasoulis A,Androulakis E,Christophides T,Tousoulis D. .2016 .The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev, 21(2) : 169-76.
Butts B,Gary RA,Dunbar SB,Butler J. .2015 .The importance of NLRP3 inflammasome in heart failure. J Card Fail, 04(7) : 586-93.
Eslick GD,Thampan BV,Nalos M,McLean AS,Sluyter R.,Circulating R. .2008 .-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int J Cardiol, 05(1) : 81-3.
Otani H. .2009 .The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal, 11(8) : 1913-28.
Vaduganathan M,Greene SJ,Butler J,Sabbah HN,Shantsila E,Lip GYH .2013 .The immunological axis in heart failure: importance of the leukocyte diferential. Heart Fail Rev, 18(6) : 835-45.
Kim SR,Lee SG,Kim SH,Kim JH,Choi E,Cho W .2020 .SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun, 11(1) : 2127.
Bolinder J,Ljunggren Ö,Kullberg J,Johansson L,Wilding J,Langkilde AM .2012 .Efects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab, 97(3) : 2260-31.
Ferrannini G,Hach T,Crowe S,Sanghvi A,Hall KD,Ferrannini E .2015 .Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care, 38(9) : 0355-5.
Lee PC,Ganguly S,Goh SY .2018 .Weight loss associated with sodiumglucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev, 19(12) : 1630-41.
Sano M. .2017 .A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol, 12(5) : 471-6.
Sano M. Hemodynamic .2017 .Efects of Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Med Res, 9(6) : 457-60.
Sano M,Chen S,Imazeki H,Ochiai H,Seino Y. .2018 .Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig, 9(3) : 638-41.
Pabel S,Hamdani N,Luedde M,Sossalla S. .2021 .SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled?. Curr Heart Fail Rep, 18(5) : 315-28.
Grubić Rotkvić P,Cigrovski Berković M,Bulj N,Rotkvić L .2020 .Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart Fail Rev, 25(6) : 899-905.
Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE,Drazner MH .2013 .ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol, 05(16) : e147-239.
Felker GM,Thompson RE,Hare JM,Hruban RH,Clemetson DE,Howard DL .2000 .Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med, 342(15) : 1077-84.
Passino C,Barison A,Vergaro G,Gabutti A,Borrelli C,Emdin M .2014 .Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta, 09 : 29-38.
Zhou H,Wang S,Zhu P,Hu S,Chen Y,Ren J .2017 .Empagliflozin rescues diabetic myocardial microvascular injury via AMPKmediated inhibition of mitochondrial fission. Redox Biol, 12 : 335-46.
Bailey CJ .2019 .Uric acid and the cardio-renal efects of SGLT2 inhibitors. Diabetes Obes Metab, 21(6) : 1291-8.
Lytvyn Y,Perkins BA,Cherney DZ .2014 .Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes, 10(3) : 239-46.
Zhao Y,Xu L,Tian D,Xia P,Zheng H,Wang L .2018 .Efects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab, 20(2) : 458-62.
Lambers Heerspink HJ,de Zeeuw D,Wie L,Leslie B,List J.,Dapagliflozin J. .2013 .a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab, 15(9) : 853-62.
Hallow KM,Helmlinger G,Greasley PJ,McMurray JJV,Boulton DW .2018 .Why do SGLT2 inhibitors reduce heart failure hospitalization? A diferential volume regulation hypothesis. Diabetes Obes Metab, 20(3) : 479-87.
0

Citations

0

Downloads

25

Views